Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20113825 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Carboplatin

Indicates status has not been verified in more than two years